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Antiestrogen therapies targeting estrogen receptor α (ER) signaling are a mainstay for
patients with ER+ breast cancer. While many cancers exhibit resistance to antiestrogen
therapies, a large body of clinical and experimental evidence indicates that hyperactivation
of the phosphatidylinositol 3-kinase (PI3K) pathway promotes antiestrogen resistance. In
addition, continued ligand-independent ER signaling in the setting of estrogen deprivation
may contribute to resistance to endocrine therapy. PI3K activates several proteins which
promote cell cycle progression and survival. In ER+ breast cancer cells, PI3K promotes
ligand-dependent and -independent ER transcriptional activity. Models of antiestrogen-
resistant breast cancer often remain sensitive to estrogen stimulation and PI3K inhibition,
suggesting that clinical trials with combinations of drugs targeting both the PI3K and ER
pathways are warranted. Herein, we review recent ﬁndings on the roles of PI3K and ER
in antiestrogen resistance, and clinical trials testing drug combinations which target both
pathways. We also discuss the need for clinical investigation of ER downregulators in
combination with PI3K inhibitors.
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INTRODUCTION
At least 75% of breast cancers express estrogen receptor α (ER)
and/or progesterone receptor (PR), which are tumor biomark-
ers of estrogen dependence. Antiestrogen treatments for patients
with ER+ or PR+ breast cancer inhibit ER by antagonizing estro-
gen ligand binding to ER (tamoxifen and other selective estrogen
receptor modulators, SERMs), inhibiting dimerization and down-
regulating ER (fulvestrant and other selective estrogen receptor
downregulators, SERDs), or blocking estrogen production (aro-
matase inhibitors, AIs; letrozole, anastrozole, exemestane). While
such endocrine therapies have changed the natural history of ER+
breast cancer, many tumors exhibit de novo or acquired drug
resistance (Table 1). The only clinically validated mechanism of
resistance to endocrine therapy is overexpression or ampliﬁca-
tion of the ERBB2 (HER2) protooncogene (Arpino et al., 2004;
De Laurentiis et al., 2005; Ellis et al., 2006). However, only 10%
of ER+ breast cancers exhibit HER2 overexpression, prompt-
ing the need for discovery of other mechanisms of antiestrogen
resistance.
A large body of experimental and clinical evidence suggests
that hyperactivation of the phosphatidylinositol 3-kinase (PI3K)
pathway, the most frequently mutated pathway in breast cancer,
promotes antiestrogen resistance. PI3K is commonly activated by
growth factor receptor tyrosine kinases and G-protein-coupled
receptors in breast cancer cells. The signaling cascades triggered by
PI3K, including PDK1,AKT, and SGK among others, promote cell
growth and survival. For detailed information, we refer the reader
to a recently published, comprehensive review of this material
(Miller et al., 2011a). Herein,we focus onupdatedﬁndings, clinical
testing of drug combinations targeting the ER and PI3K pathways,
and the need to clinically address the potential for continued ER
signaling in patients treated with endocrine therapies.
RATIONALE FOR COMBINED TARGETING OF THE ER AND
PI3K PATHWAYS
We and others identiﬁed a requirement for PI3K in the estrogen-
independent growth of long-term estrogen-deprived (LTED) ER+
breast cancer cells, which mirror clinical resistance to AIs (Sabnis
et al., 2007; Crowder et al., 2009; Miller et al., 2010). Proteomic
proﬁling revealed ampliﬁcation of PI3K signaling via the mTOR
substrates p70S6 kinase and p85S6 kinase, and the PI3K effec-
tor AKT in ER+ human breast cancer cells adapted to hormone
deprivation. Treatment with the ATP-competitive PI3K/mTOR
dual inhibitor BEZ235 (Maira et al., 2008) completely suppressed
the emergence of hormone-independent ER+ cells and induced
apoptosis in cell lines harboring activating mutations in PIK3CA
(gene that encodes the p110α subunit of PI3K) or PTEN loss
(PTEN antagonizes PI3K signaling). In contrast, the TORC1
inhibitor everolimus (Schuler et al., 1997) had only a partial effect
(Miller et al., 2010; Sanchez et al., 2011). This partial effect may
be attributable to feedback activation of PI3K/AKT upon inhibi-
tion of TORC1 (O’Reilly et al., 2006; Carracedo et al., 2008; Miller
et al., 2009), suggesting that direct inhibitors of PI3Kmay bemore
effective than rapalogs in this setting.
In a siRNA screen against 779 kinases, we implicated insulin
receptor (InsR) in the hormone-independent growth of MCF-
7/LTED cells. InsR and its homolog IGF-1R dimerize and, upon
ligand binding, potently activate PI3K. IGF-1R has also been
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Table 1 | Frequencies of breast cancer recurrence and resistance to anti-estrogen therapies in patients with ER+ breast cancer.
Population Treatment Effect Trial/reference
Early-stage
Post-menopausal
Adjuvant anastrozole × 5 years
Adjuvant tamoxifen × 5 years
Follow-up: 5 years 10 years
Distant recurrence: 9.8% 19.7%
Distant recurrence: 12.5% 24%
ATAC (Cuzick et al., 2010)
Early-stage
Post-menopausal
Adjuvant letrozole × 5 years
Adjuvant tamoxifen × 5 years
Follow-up: 5 years 8 years
Recurrence: 14.5% 23.6%
Recurrence: 18% 28%
BIG 1-98 (Regan et al., 2011)
Advanced
Post-menopausal
No prior Tx
Anastrozole
Fulvestrant (high-dose regimen)
No clinical beneﬁt: 33%
No clinical beneﬁt: 27.5%
FIRST (Robertson et al., 2009a)
Advanced
Post-menopausal
Progressed on AI
Exemestane
Fulvestrant (loading-dose regimen)
No clinical beneﬁt: 68.5%
No clinical beneﬁt: 67.8%
EFECT (Chia et al., 2008)
Disease-free following
5 years of adjuvant tamoxifen
Letrozole
Placebo
Median follow-up: 5.3 years
With disease: 2%
With disease: 4.9%
MA.17
(Goss et al., 2008)
Disease-free following
5 years of adjuvant tamoxifen
Exemestane
Placebo
Median follow-up: 2.5 years
With disease: 9%
With disease: 11%
NSABP B-33
(Mamounas et al., 2008)
shown to confer antiestrogen resistance in MCF-7 cells (Zhang
et al., 2011). Treatment with the ATP-competitive IGF-1R/InsR
inhibitor OSI-906 suppressed PI3K activation and hormone-
independent ER+ cell growth (Fox et al., 2011). Networkmapping
of the 42 kinases individually implicated in MCF-7/LTED cell
growth in this screen revealed that PI3K is a central hub in
these signaling pathways (Figure 1). Interestingly, a recent study
showed that in ER+ breast cancer cells treated with BEZ235 or
with PI3K siRNA, exogenous 17β-estradiol rescued the cells from
drug- and siRNA-induced apoptosis (Crowder et al., 2009; Sanchez
et al., 2011). This suggests that in ER+ cancers treated with PI3K
inhibitors, estrogen suppression should be maintained and, there-
fore, combined inhibition of both PI3K and ER may be more
effective than single-agent therapies.
Clinical evidence further indicates that PI3K pathway activa-
tion is associated with antiestrogen resistance. Patients bearing
primary ER+ breast tumors which exhibit a protein expres-
sion/phosphorylation signature of PI3K activation, as deter-
mined using reverse-phase protein arrays (RPPA), have a shorter
recurrence-free survival (Miller et al., 2010). RPPAanalysis of ER+
primary breast tumors obtained frompatients following 2–3weeks
of treatment with the AI letrozole showed that a protein signa-
ture of insulin signaling was associated with high post-AI tumor
cell proliferation (Fox et al., 2011). Overexpression of HER2 or
FGFR1, or loss of INPP4B, molecular lesions which activate the
PI3K pathway, also confer antiestrogen resistance in patients with
ER+ breast cancer (Arpino et al., 2004; De Laurentiis et al., 2005;
Ellis et al., 2006; Gewinner et al., 2009; Turner et al., 2010). Also
noteworthy is the inverse correlation between levels of PI3K acti-
vation and ER protein in human tumors. This ER/PI3K balance
can be shifted using PI3K and ER inhibitors in preclinical models
(Figure 2; Creighton et al., 2010; Miller et al., 2010), suggesting
that cells may defer to the other pathway when one is inhibited.
Crosstalk between the PI3K and ER pathways has also been
suggested as a mechanism of endocrine resistance (Musgrove
and Sutherland, 2009). PI3K activation was shown to induce
ER phosphorylation at the putative AKT/p70S6K site Ser167 and
estrogen-independent transcriptional activity (Campbell et al.,
2001; Yamnik et al., 2009). However, treatment of such cells in
hormone-depleted conditions with everolimus or the pan-PI3K
inhibitor BKM120 (Maira et al., 2012) did not decrease ER phos-
phorylation at Ser167, ER-DNA binding, or ER transcriptional
reporter activity (Miller et al., 2011b). These data collectively
suggest that PI3K effectors do not modulate ER in the absence
of estrogens. Analysis of the effects of BKM120 and fulves-
trant on hormone-independent cell growth showed synergy in
6/8 ER+ lines. In mice bearing ER+ breast cancer xenografts,
single-agent treatment with BKM120 or fulvestrant slowed tumor
growth, while the combination induced tumor regression. Sim-
ilarly, treatment with the ATP-competitive IGF-1R/InsR dual
inhibitorOSI-906, which blocks downstream activation of PI3K in
MCF-7 cells, slowed tumor growth and induced regression when
combined with fulvestrant (Fox et al., 2011). These data further
imply that combined targeting of the ER and PI3K pathways is
more effective than single-agent therapies.
CLINICAL TRIALS TESTING DRUG COMBINATIONS
TARGETING THE ER AND PI3K PATHWAYS
Herein, we will review three recent clinical studies that evalu-
ated the beneﬁt of adding the TORC1 inhibitor everolimus to
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FIGURE 1 | Phosphatidylinositol 3-kinase is a central hub in signaling
pathways required for estrogen-independent ER+ breast cancer
cell growth. MCF-7/LTED cells transiently transfected with a siRNA
library targeting 779 kinases were reseeded in hormone-depleted
medium. Cell viability was measured 4–5 days later by Alamar blue
assay. Median cell growth in four independent experiments was
calculated for each kinase siRNA relative to non-silencing controls.
Individual knockdown of 42 kinases inhibited MCF-7/LTED cell growth
≥33% (p ≤ 0.05) in at least three of four experiments (detailed in
Fox et al., 2011). Ingenuity Pathways Analysis revealed that these 42
kinases map to several protein networks that overlap with PI3K
signaling (red box, enlarged in bottom panel). Proteins involved in these
networks are displayed as nodes. Solid lines indicate direct relationships
between proteins, and dotted lines indicate indirect interactions. Green
nodes represent the kinases identiﬁed in the screen, as well as others
whose knockdown was predicted by the Ingenuity software to negatively
affect cell growth. The various nodal shapes represent the functional class
of the gene product.
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FIGURE 2 | Estrogen receptor inhibition with fulvestrant induces
upregulation of PI3K signaling. Ovariectomized athymic mice were s.c.
implanted with MCF-7 cells and a 10-day-release E2 pellet (0.12 mg). Twelve
days later, mice were randomized to treatment with vehicle or fulvestrant
(5 mg/week, s.c., clinical formulation). Tumors were harvested after 3–4
weeks of treatment. Tumor lysates were analyzed by immunoblotting using
the indicated antibodies; each lane contains equal amount of protein from
two to three tumors. Fulvestrant treatment decreased the levels of ER and
ER-regulated genes products (PR, IGF-1R), but increased levels of
P-AKT-T308 and P-AKT-S473, suggesting increased activation of PI3K. All
lanes were from the same membrane.
FIGURE 3 | Diagram of a clinical trial with a PI3K pathway inhibitor
in AI-resistant breast cancer. Patients with breast cancer that progressed
on AI therapy will be subjected to a biopsy to conﬁrm ER+, HER2-negative,
PIK3CA-mutant status. Eligible patients would then be randomized to
another AI plus a PI3K inhibitor, or fulvestrant plus the PI3K inhibitor.
FDG-PET scans would be performed before and after 4 weeks of
therapy to identify early metabolic changes. Patients will be treated
until progression.
endocrine therapy. (1) In the ﬁrst study, post-menopausal women
with early-stage ER+ breast cancer were randomized to neoad-
juvant therapy with the AI letrozole ± everolimus for 4 months.
The addition of everolimus increased clinical response and sup-
pression of tumor cell proliferation at 2 weeks (measured by Ki67
IHC) compared to letrozole alone (Baselga et al., 2009). (2) In the
TAMRAD study, post-menopausal patients with metastatic, ER+,
AI-resistant breast cancer were randomized to treatment with
tamoxifen ± everolimus. The addition of everolimus improved
clinical beneﬁt rate, time-to-progression, and disease-free sur-
vival compared to tamoxifen alone (Bachelot et al., 2010). (3)
The phase III BOLERO-2 study included 724 post-menopausal
womenwithmetastatic, ER+, HER2-negative breast cancer.While
84% of patients exhibited sensitivity to prior endocrine therapy,
all were resistant to non-steroidal AIs (letrozole, anastrozole) at
the time of randomization to treatment with the steroidal AI
exemestane ± everolimus. The addition of everolimus increased
progression-free survival (PFS) from 4.1 months (exemestane
alone) to 10.6 months (Baselga et al., 2012).
While the addition of a TORC1 inhibitor prevents disease
progression in patients with antiestrogen-resistant breast can-
cer, inhibition of TORC1 relieves negative feedback on activators
of PI3K (e.g., IGF-1R, IRS-1, HER3; O’Reilly et al., 2006; Car-
racedo et al., 2008; Miller et al., 2009). These data suggest that
direct inhibitors of PI3K may be more effective. Early clini-
cal testing of PI3K inhibitors in combination with antiestrogens
suggests that this strategy is feasible. In a phase Ib trial, post-
menopausal patients with advanced ER+ disease are being treated
with letrozole plus the PI3K inhibitor BKM120. This drug
combination is safe and exhibits promising anti-tumor activity
(Mayer et al., 2012).
RATIONALE FOR AN ER DOWNREGULATOR IN COMBINATION
WITH A PI3K INHIBITOR IN AI-RESISTANT BREAST CANCER
A recent comparison of high-dose fulvestrant (an ER downreg-
ulator) to the AI anastrozole as ﬁrst-line treatment for advanced
breast cancer revealed that fulvestrant provided a longer time-
to-progression (Robertson et al., 2009a). In other studies, ∼35%
of patients who progressed on an AI responded to second-line
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fulvestrant (Ingle et al., 2006; Perey et al., 2007). This suggests
that in some clinical situations, downregulation of ER may be
superior to estrogen deprivation (AI) therapy (Robertson et al.,
2009a).We recently reported that ER retains transcriptional activ-
ity in estrogen-independent LTED cells and primary human breast
tumors (i.e., following AI therapy), and drives the estrogen-
independent growth of LTED cells (Miller et al., 2011b). These
data suggest that estrogen (ligand)-independent ER activity may
promote resistance to AI therapy. While their side effect proﬁles
are generally similar,AI therapy increases the risk of bone fractures
and joint disorders more so than fulvestrant (Howell et al., 2002,
2005; Osborne et al., 2002; Goss et al., 2003; Robertson et al., 2003;
Howell and Sapunar, 2011). Fulvestrant, which is administered
intramuscularly, is associated with injection site pain, and only
induces partial ER downregulation in tumors (Robertson et al.,
2009b). Hence, the development of a more potent, orally avail-
able ER downregulator/inhibitor may provide a convenient and
effective treatment option for patients with ER+ breast cancer.
Cancer cells harboring activating mutations in PIK3CA exhibit
increased sensitivity toPI3K inhibition (Miller et al., 2010; Sanchez
et al., 2011; Maira et al., 2012), suggesting that this class of drugs
may be most effective against tumors with mutations in the PI3K
pathway. In mice bearing ER+, HER2-negative, PIK3CA-mutant
MCF-7 breast cancer xenografts, treatment with the combina-
tion of fulvestrant and BKM120 induced tumor regression (Miller
et al., 2011b). Using [18F]FDG-PET imaging as an early biomarker
of metabolic inhibition, treatment with BKM120 but not fulves-
trant decreased tumor FDG uptake. BKM120 increased tumor cell
apoptosis, while fulvestrant decreased tumor cell proliferation.
These ﬁndings may be validated clinically in a phase II clini-
cal trial where post-menopausal patients with AI-resistant, ER+,
HER2-negative, PIK3CA-mutant breast cancer are randomized to
treatment with another AI plus a PI3K inhibitor vs. fulvestrant
plus a PI3K inhibitor (Figure 3). The novel agent in such a trial
would be the PI3K inhibitor, but the comparison would be an AI
vs. fulvestrant. The primary endpoint would be PFS. Incorpora-
tion of non-invasive imaging with [18F]FDG-PET at baseline and
after several weeks of treatment could identify metabolic changes
indicative of a pharmacodynamic effect. This comparison would
inform us whether (1) the addition of a PI3K inhibitor to an AI
is beneﬁcial, (2) downregulation of ER is superior to estrogen
deprivation (AI) therapy in the context of PI3K inhibition, and
(3) metabolic inhibition at an early time point as reﬂected by
FDG-PET is predictive of PFS.
ACKNOWLEDGMENTS
This work was supported by the National Institutes of Health
K99CA142899, R00CA142899 (Todd W. Miller), Breast Can-
cer Specialized Program of Research Excellence (SPORE)
P50CA98131, Vanderbilt-Ingram Cancer Center Support Grant
P30CA68485; a grant from theBreast Cancer Research Foundation
(Carlos L. Arteaga); American Cancer Society Clinical Research
Professorship Grant CRP-07-234 (Carlos L. Arteaga) and Post-
doctoral Fellowship Grant PF-10-184-01-TBE (EmilyM. Fox); the
Lee Jeans Translational Breast Cancer Research Program (Carlos L.
Arteaga); and Stand Up to Cancer/American Association for Can-
cer Research Dream Team Translational Cancer Research Grant
SU2C-AACR-DT0209 (Carlos L. Arteaga).
REFERENCES
Arpino, G., Green, S. J., Allred, D. C.,
Lew, D., Martino, S., Osborne, C.
K., et al. (2004). HER-2 ampliﬁca-
tion, HER-1 expression, and tamox-
ifen response in estrogen receptor-
positive metastatic breast cancer: a
southwest oncology group study.
Clin. Cancer Res. 10, 5670–5676.
Bachelot, T., Bourgier, C., Cropet, C.,
Guastalla, J.-P., Ferrero, J.-M., Leger-
Falandry, C., et al. (2010). TAMRAD:
a GINECO randomized phase II trial
of everolimus in combination with
tamoxifen versus tamoxifen alone in
patients (pts)withhormone-receptor
positive, HER2 negative metastatic
breast cancer (MBC)with prior expo-
sure to aromatase inhibitors (AI).
Cancer Res. 70, abstract S1–S6.
Baselga, J., Campone, M., Piccart, M.,
Burris, H. A. III, Rugo, H. S., Sah-
moud, T., et al. (2012). Everolimus in
postmenopausal hormone-receptor-
positive advanced breast cancer. N.
Engl. J. Med. 366, 520–529.
Baselga, J., Semiglazov, V., Van Dam,
P., Manikhas, A., Bellet, M., May-
ordomo, J., et al. (2009). Phase II
randomized study of neoadjuvant
everolimus plus letrozole compared
with placebo plus letrozole in patients
with estrogen receptor-positive breast
cancer. J. Clin. Oncol. 27, 2630–2637.
Campbell, R. A., Bhat-Nakshatri, P.,
Patel, N. M., Constantinidou, D.,
Ali, S., and Nakshatri, H. (2001).
Phosphatidylinositol 3-kinase/AKT-
mediated activation of estrogen
receptor alpha: a new model for anti-
estrogen resistance. J. Biol. Chem.
276, 9817–9824.
Carracedo, A., Ma, L., Teruya-Feldstein,
J., Rojo, F., Salmena, L., Alimonti, A.,
et al. (2008). Inhibition of mTORC1
leads to MAPK pathway activation
through a PI3K-dependent feedback
loop in human cancer. J. Clin. Invest.
118, 3065–3074.
Chia, S., Gradishar, W., Mauriac, L.,
Bines, J., Amant, F., Federico, M.,
et al. (2008). Double-blind, ran-
domized placebo controlled trial of
fulvestrant compared with exemes-
tane after prior nonsteroidal aro-
matase inhibitor therapy in post-
menopausal women with hormone
receptor-positive, advanced breast
cancer: results from EFECT. J. Clin.
Oncol. 26, 1664–1670.
Creighton, C. J., Fu, X., Hennessy, B.
T., Casa, A. J., Zhang, Y., Gonzalez-
Angulo, A. M., et al. (2010). Pro-
teomic and transcriptomic proﬁling
reveals a link between the PI3K path-
way and lower estrogen receptor (ER)
levels and activity in ER+ breast
cancer. Breast Cancer Res. 12, R40.
Crowder, R. J., Phommaly, C., Tao,
Y., Hoog, J., Luo, J., Perou, C. M.,
et al. (2009). PIK3CA and PIK3CB
inhibition produce synthetic lethal-
ity when combined with estrogen
deprivation in estrogen receptor-
positive breast cancer. Cancer Res. 69,
3955–3962.
Cuzick, J., Sestak, I., Baum, M., Buz-
dar, A., Howell, A., Dowsett, M.,
et al. (2010). Effect of anastrozole
and tamoxifen as adjuvant treatment
for early-stage breast cancer: 10-year
analysis of the ATAC trial. Lancet
Oncol. 11, 1135–1141.
De Laurentiis, M., Arpino, G., Mas-
sarelli, E., Ruggiero, A., Carlo-
magno, C., Ciardiello, F., et al.
(2005). A meta-analysis on the inter-
action between HER-2 expression
and response to endocrine treatment
in advanced breast cancer. Clin. Can-
cer Res. 11, 4741–4748.
Ellis, M. J., Tao, Y., Young, O., White, S.,
Proia, A. D., Murray, J., et al. (2006).
Estrogen-independent prolifera-
tion is present in estrogen-receptor
HER2-positive primary breast cancer
after neoadjuvant letrozole. J. Clin.
Oncol. 24, 3019–3025.
Fox, E. M., Miller, T. W., Balko, J. M.,
Kuba,M.G., Sanchez,V., Smith, R.A.,
et al. (2011). A kinome-wide screen
identiﬁes the insulin/IGF-I receptor
pathway as a mechanism of escape
from hormone dependence in breast
cancer. Cancer Res. 71, 6773–6784.
Gewinner, C., Wang, Z. C., Richardson,
A., Teruya-Feldstein, J., Etemad-
moghadam, D., Bowtell, D., et al.
(2009). Evidence that inositol
polyphosphate 4-phosphatase type
II is a tumor suppressor that inhibits
PI3K signaling. Cancer Cell 16,
115–125.
Goss, P. E., Ingle, J. N., Martino, S.,
Robert, N. J., Muss, H. B., Piccart, M.
J., et al. (2003). A randomized trial of
letrozole in postmenopausal women
after ﬁve years of tamoxifen therapy
for early-stage breast cancer. N. Engl.
J. Med. 349, 1793–1802.
Goss, P. E., Ingle, J. N., Pater, J. L., Mar-
tino, S., Robert, N. J., Muss, H. B.,
et al. (2008). Late extended adjuvant
treatment with letrozole improves
outcome in women with early-stage
breast cancer who complete 5 years
of tamoxifen. J. Clin. Oncol. 26,
1948–1955.
www.frontiersin.org October 2012 | Volume 2 | Article 145 | 5
“fonc-02-00145” — 2012/10/15 — 10:50 — page 6 — #6
Fox et al. ER and PI3K in endocrine resistance
Howell, A., Cuzick, J., Baum, M., Buz-
dar, A., Dowsett, M., Forbes, J. F.,
et al. (2005). Results of the ATAC
(Arimidex, Tamoxifen, Alone or in
Combination) trial after completion
of 5 years’ adjuvant treatment for
breast cancer. Lancet 365, 60–62.
Howell, A., Robertson, J. F., Quaresma
Albano, J., Aschermannova, A., Mau-
riac, L., Kleeberg, U. R., et al. (2002).
Fulvestrant, formerly ICI 182,780, is
as effective as anastrozole in post-
menopausal women with advanced
breast cancer progressing after prior
endocrine treatment. J. Clin. Oncol.
20, 3396–3403.
Howell, A., and Sapunar, F. (2011). Ful-
vestrant revisited: efﬁcacy and safety
of the 500-mg dose. Clin. Breast
Cancer 11, 204–210.
Ingle, J. N., Suman, V. J., Rowland,
K. M., Mirchandani, D., Bernath,
A. M., Camoriano, J. K., et al.
(2006). Fulvestrant in women with
advanced breast cancer after progres-
sion on prior aromatase inhibitor
therapy: North Central Cancer Treat-
ment Group Trial N0032. J. Clin.
Oncol. 24, 1052–1056.
Maira, S. M., Pecchi, S., Huang, A.,
Burger, M., Knapp, M., Sterker, D.,
et al. (2012). Identiﬁcation and char-
acterization of NVP-BKM120, an
orally available pan-class I PI3-kinase
inhibitor. Mol. Cancer Ther. 11,
317–328.
Maira, S. M., Stauffer, F., Brueggen,
J., Furet, P., Schnell, C., Fritsch, C.,
et al. (2008). Identiﬁcation and char-
acterization of NVP-BEZ235, a new
orally available dual phosphatidyli-
nositol 3-kinase/mammalian target
of rapamycin inhibitor with potent in
vivo antitumor activity. Mol. Cancer
Ther. 7, 1851–1863.
Mamounas, E. P., Jeong, J. H., Wick-
erham, D. L., Smith, R. E., Ganz, P.
A., Land, S. R., et al. (2008). Beneﬁt
from exemestane as extended adju-
vant therapy after 5 years of adjuvant
tamoxifen: intention-to-treat analy-
sis of the National Surgical Adjuvant
Breast And Bowel Project B-33 trial.
J. Clin. Oncol. 26, 1965–1971.
Mayer, I. A., Abramson, V. G., Balko,
J. M., Isakoff, S. J., Kuba, M.
G., Sanders, M., et al. (2012).
SU2C phase Ib study of pan-PI3K
inhibitor BKM120 with letrozole in
ER+/HER2− metastatic breast can-
cer (MBC). J. Clin. Oncol. 30(Suppl.),
abstract 510.
Miller, T. W., Balko, J. M., and Arteaga,
C. L. (2011a). Phosphatidylinositol
3-kinase and antiestrogen resistance
in breast cancer. J. Clin. Oncol. 29,
4452–4461.
Miller, T. W., Balko, J. M., Fox, E. M.,
Ghazoui, Z., Dunbier, A., Anderson,
H., et al. (2011b). ERα-dependent
E2F transcription can mediate resis-
tance to estrogen deprivation in
human breast cancer. Cancer Discov.
1, 338–351.
Miller, T. W., Forbes, J. T., Shah,
C., Wyatt, S. K., Manning, H.
C., Olivares, M. G., et al. (2009).
Inhibition of mammalian target of
rapamycin is required for optimal
antitumor effect of HER2 inhibitors
against HER2-overexpressing cancer
cells.Clin. Cancer Res. 15, 7266–7276.
Miller, T.W., Hennessy, B. T., Gonzalez-
Angulo, A. M., Fox, E. M., Mills, G.
B., Chen, H., et al. (2010). Hyper-
activation of phosphatidylinositol-
3 kinase promotes escape from
hormone dependence in estrogen
receptor-positive human breast can-
cer. J. Clin. Invest. 120, 2406–2413.
Musgrove, E. A., and Sutherland, R.
L. (2009). Biological determinants of
endocrine resistance in breast cancer.
Nat. Rev. Cancer 9, 631–643.
O’Reilly, K. E., Rojo, F., She, Q.
B., Solit, D., Mills, G. B., Smith,
D., et al. (2006). mTOR inhibition
induces upstream receptor tyrosine
kinase signaling and activates Akt.
Cancer Res. 66, 1500–1508.
Osborne, C. K., Pippen, J., Jones, S.
E., Parker, L. M., Ellis, M., Come,
S., et al. (2002). Double-blind, ran-
domized trial comparing the efﬁcacy
and tolerability of fulvestrant ver-
sus anastrozole in postmenopausal
women with advanced breast cancer
progressing on prior endocrine ther-
apy: results of aNorthAmerican trial.
J. Clin. Oncol. 20, 3386–3395.
Perey, L., Paridaens, R., Hawle, H.,
Zaman, K., Nole, F., Wildiers, H.,
et al. (2007). Clinical beneﬁt of ful-
vestrant in postmenopausal women
with advanced breast cancer and pri-
mary or acquired resistance to aro-
matase inhibitors: ﬁnal results of
phase II Swiss Group for Clinical
Cancer Research Trial (SAKK 21/00).
Ann. Oncol. 18, 64–69.
Regan, M. M., Neven, P., Giobbie-
Hurder, A., Goldhirsch, A., Ejlert-
sen, B., Mauriac, L., et al. (2011).
Assessment of letrozole and tamox-
ifen alone and in sequence for post-
menopausal womenwith steroid hor-
mone receptor-positive breast cancer:
the BIG1-98 randomised clinical trial
at 8.1 years median follow-up. Lancet
Oncol. 12, 1101–1108.
Robertson, J. F., Llombart-Cussac, A.,
Rolski, J., Feltl, D., Dewar, J.,
Macpherson, E., et al. (2009a). Activ-
ity of fulvestrant 500 mg versus anas-
trozole 1mg as ﬁrst-line treatment for
advanced breast cancer: results from
the FIRST study. J. Clin. Oncol. 27,
4530–4535.
Robertson, J. F. R., Dixon, J. M., Sib-
bering, D. M., Jahan, A., Ellis, I.
O., Channon, E. J., et al. (2009b).
Tumor biomarker changes following
pre-surgical treatment with 500 mg
fulvestrant plus anastrozole versus
500 mg fulvestrant alone and 1 mg
anastrozole alone. Cancer Res. 69,
abstract 24.
Robertson, J. F., Osborne, C. K., How-
ell, A., Jones, S. E., Mauriac, L., Ellis,
M., et al. (2003). Fulvestrant ver-
sus anastrozole for the treatment of
advanced breast carcinoma in post-
menopausal women: a prospective
combined analysis of twomulticenter
trials. Cancer 98, 229–238.
Sabnis, G., Goloubeva, O., Jelovac, D.,
Schayowitz,A., andBrodie,A. (2007).
Inhibition of the phosphatidylinos-
itol 3-kinase/Akt pathway improves
response of long-term estrogen-
deprived breast cancer xenografts to
antiestrogens. Clin. Cancer Res. 13,
2751–2757.
Sanchez, C. G., Ma, C. X., Crow-
der, R. J., Guintoli, T., Phom-
maly, C., Gao, F., et al. (2011).
Preclinical modeling of combined
phosphatidylinositol-3-kinase inhi-
bition with endocrine therapy for
estrogen receptor-positive breast can-
cer. Breast Cancer Res. 13, R21.
Schuler, W., Sedrani, R., Cottens, S.,
Haberlin, B., Schulz, M., Schu-
urman, H. J., et al. (1997). SDZ
RAD, a new rapamycin derivative:
pharmacological properties in vitro
and in vivo. Transplantation 64,
36–42.
Turner, N., Pearson, A., Sharpe, R.,
Lambros,M.,Geyer, F., Lopez-Garcia,
M.A., et al. (2010). FGFR1 ampliﬁca-
tion drives endocrine therapy resis-
tance and is a therapeutic target in
breast cancer. Cancer Res. 70, 2085–
2094.
Yamnik, R. L., Digilova, A., Davis, D. C.,
Brodt, Z. N., Murphy, C. J., and Holz,
M. K. (2009). S6 kinase 1 regulates
estrogen receptor alpha in control of
breast cancer cell proliferation. J. Biol.
Chem. 284, 6361–6369.
Zhang, Y., Moerkens, M., Ramaiah-
gari, S., De Bont, H., Price, L.,
Meerman, J., et al. (2011). Elevated
insulin-like growth factor 1 recep-
tor signaling induces antiestrogen
resistance through the MAPK/ERK
and PI3K/Akt signaling routes. Breast
Cancer Res. 13, R52.
Conflict of Interest Statement: The
authors declare that the research was
conducted in the absence of any com-
mercial or ﬁnancial relationships that
could be construed as a potential con-
ﬂict of interest.
Received: 21 August 2012; paper pending
published: 18 September 2012; accepted:
30 September 2012; published online: 16
October 2012.
Citation: Fox EM, Arteaga CL and Miller
TW (2012) Abrogating endocrine resis-
tance by targeting ERα and PI3K in
breast cancer. Front. Oncol. 2:145. doi:
10.3389/fonc.2012.00145
This article was submitted to Frontiers
in Molecular and Cellular Oncology, a
specialty of Frontiers in Oncology.
Copyright © 2012 Fox, Arteaga and
Miller. This is an open-access article dis-
tributed under the terms of the Creative
Commons Attribution License, which
permits use, distribution and reproduc-
tion in other forums, provided the origi-
nal authors and source are credited and
subject to any copyright notices concern-
ing any third-party graphics etc.
Frontiers in Oncology | Molecular and Cellular Oncology October 2012 | Volume 2 | Article 145 | 6
